Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low – Should You Sell?

Janux Therapeutics, Inc. (NASDAQ:JANX)’s stock price reached a new 52-week low during trading on Thursday . The stock traded as low as $12.72 and last traded at $12.8310, with a volume of 445755 shares changing hands. The stock had previously closed at $13.33.

Analyst Ratings Changes

Several equities analysts have issued reports on JANX shares. Cantor Fitzgerald cut their price target on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating on the stock in a report on Tuesday, December 2nd. Piper Sandler cut their price objective on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, January 16th. Clear Str lowered Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. UBS Group reaffirmed a “buy” rating and issued a $57.00 price objective on shares of Janux Therapeutics in a report on Tuesday, December 2nd. Finally, Stifel Nicolaus decreased their target price on Janux Therapeutics from $46.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Eleven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $60.08.

Janux Therapeutics Trading Down 5.5%

The stock has a market cap of $757.59 million, a PE ratio of -7.49 and a beta of 2.88. The company has a fifty day moving average of $15.61 and a 200-day moving average of $22.06.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.21. The company had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $3.07 million. As a group, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 1,879 shares of Janux Therapeutics stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $25,798.67. Following the sale, the insider owned 83,095 shares of the company’s stock, valued at $1,140,894.35. The trade was a 2.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Charles M. Winter sold 2,401 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $32,965.73. Following the completion of the transaction, the insider directly owned 77,721 shares of the company’s stock, valued at $1,067,109.33. The trade was a 3.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 25,699 shares of company stock worth $471,235 in the last ninety days. Company insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in shares of Janux Therapeutics by 71.7% in the 1st quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock worth $262,000 after acquiring an additional 4,059 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Janux Therapeutics by 18.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company’s stock worth $583,000 after acquiring an additional 3,393 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Janux Therapeutics by 12.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company’s stock worth $5,033,000 after purchasing an additional 20,657 shares during the last quarter. Aberdeen Group plc increased its position in Janux Therapeutics by 26.9% in the 2nd quarter. Aberdeen Group plc now owns 285,288 shares of the company’s stock valued at $6,590,000 after acquiring an additional 60,500 shares during the period. Finally, FNY Investment Advisers LLC raised its stake in shares of Janux Therapeutics by 111.8% during the second quarter. FNY Investment Advisers LLC now owns 5,210 shares of the company’s stock valued at $120,000 after purchasing an additional 2,750 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.